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Rationale: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 is
based on an ABCD assessment tool of symptoms and exacerbation history and grade 1–4 of
airflow limitation severity, facilitating classification either into 4 groups (ABCD) or 16 groups
(1A-4D). We aimed to compare the GOLD 2011, GOLD 2017 ABCD, and GOLD 2017 1A-
4D classifications in terms of their distribution and prediction of mortality and hospitalizations.
Methods: In the GenKOLS study, 912 COPD patients with FEV1 less than 80% of the
predicted answered questionnaires and performed lung function testing in 2003–2005. The
patients were recruited from a hospital patient registry (n=662) and from the general
population (n=250), followed up until 2011 with respect to all-cause and respiratory mortal-
ity, and all-cause and respiratory hospitalizations. We performed logistic regression and
receiver operating curve (ROC) analyses for the different classifications with estimations
of area under the curve (AUC) for comparisons.
Results: Mean age at baseline was 60 years (SD 11), 55% were male. Mean duration of
follow-up was 91 months. By GOLD 2011, 21% were classified as group A, 29% group B,
6% group C, and 43% as group D, corresponding percentages for GOLD 2017 were: 25%,
52%, 3%, and 20%. The GOLD 2011 classification had higher AUC values than the GOLD
2017 group ABCD classification for respiratory mortality and hospitalization, but after
inclusion of airflow limitation severity in GOLD 2017 groups 2A–4D, AUC values were
significantly higher with GOLD 2017.
Conclusion: In a clinically relevant sample of COPD patients, the GOLD 2017 classifica-
tion doubles the prevalence of group B and halves the prevalence of groups C and D as
compared to the GOLD 2011 classification. The prediction of respiratory mortality and
respiratory hospitalization was better for GOLD 2017 2A–4D taking airflow limitation
severity into account, as compared to GOLD 2017 ABCD and GOLD 2011.
Keywords: respiratory, hospitalization, mortality, Cox regression, ABCD classification,
airflow limitation
Introduction
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and
treatable disease that is characterized by persistent respiratory symptoms and air-
flow limitation.1 COPD is predominantly defined according to guidelines from the
Global Initiative for Chronic Obstructive Lung Disease (GOLD). The first guide-
lines were published in 1997 and have since been regularly updated with the latest
version launched in 2017.2
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The 2011 update of GOLD introduced the ABCD
groups and was a major step forward from the simple
grading of airflow limitation severity of COPD as it also
included level of respiratory symptoms and exacerbation
history in the COPD classification. However, both
Johannessen et al3 and Soriano et al4 had compared
GOLD 2007 and GOLD 2011 classifications and showed
that the 2011 classification was more complicated but did
not predict mortality and hospitalization any better than
the grading of airflow limitation severity. To meet these
concerns, the 2017 update of GOLD has separated grading
of airflow limitation severity (grade 1–4) from the ABCD
groups. Spirometry is now used to diagnose COPD and
grade airflow limitation severity, while the ABCD groups
are based on symptoms and exacerbation history and are
used to guide pharmacotherapy.
The PLATINO study5 and a Danish study by Gedebjerg
et al6 have compared the prognostic ability of the newGOLD
2017 with the GOLD 2011 classification in clinically
recruited patients. The GenKOLS study included clinically
recruited patients with FEV1<80% of the predicted and had
eight-year follow-up with respect to all-cause and respiratory
mortality and hospitalizations. The aim of the present study
was to compare the prognostic ability of the GOLD 2011
classification with the GOLD 2017 ABCD groups and the
GOLD 2017 2A–4D groups (taking both airflow limitation
severity and ABCD classification into account).
Methods
Study population
The subjects included in the present study were part of the
GenKOLS study, which was performed in the period
2003–2005. This study has previously been described in
detail.7 Briefly, the patients were recruited from a hospital
patient registry (n=662) and from the general population
(n=250) with participants with reduced FEV1. Main inclu-
sion criteria were age >40 years, >2.5 pack-years of smok-
ing history, and a post-bronchodilator FEV1/FVC <0.70 and
FEV1<80% of the predicted (full inclusion and exclusion
criteria are given in the online supplement). The participant
consent was written informed consent before inclusion in
the study, and the study was approved by the Regional
Ethics Committee in Western Norway. The study was con-
ducted in accordance with the Declaration of Helsinki.
All patients underwent clinical examination and
spirometry8 was measured.9 In addition, all patients
answered questionnaires regarding comorbidities (diabetes
type 2, heart attack and/or angina pectoris, high blood pres-
sure), smoking habits, respiratory symptoms (chronic cough,
phlegm, wheeze), and previous COPD exacerbations.10 The
modified Medical Research Council (mMRC) questionnaire
on dyspnea was also completed, but not the COPD assess-
ment test (CAT).
The patients were classified according to the GOLD 2011
and GOLD 2017 assessment tools;11 the GOLD 2011 classi-
fication of patients into four ABCD groups is based on
FEV1% of predicted, self-reported severity of dyspnea
(mMRC questionnaire), and COPD exacerbations defined
as self-reported number of exacerbations requiring predniso-
lone or antibiotics 12 months before study inclusion. The
GOLD 2017 classification of patients into four ABCD
groups is based only on self-reported severity of dyspnea
(mMRC questionnaire) and COPD exacerbations. GOLD
2017 group 2A–4D is a combination of airflow limitation
(grade 2–4) severity and GOLD 2017 ABCD groups.
Outcomes
We retrieved information on all-cause mortality and
respiratory mortality for the study participants for the
period January 2003 through June 2011 from the
National Cause of Death Registry in Norway. Respiratory
mortality was defined as main or underlying cause of death
ICD-10 codes J40 through J47. All the death certificates
were validated manually through comparing mortality
registrations with hospital registries. Information on hos-
pitalizations was collected from patient registries for the
same time period (ie, from January 2003 through
June 2011). We extracted information on total number of
hospital admissions based on all causes and based on
respiratory causes (ICD-10 codes J40 through J47) and
on total number of admission days based on all causes
and on respiratory causes.
Statistics
All statistical analyses were performed using Stata/SE 14.0
(StataCorp, College Station, TX) software for Windows.
All p-values were two-sided, and values <0.05 were con-
sidered statistically significant. We performed descriptive
analyses to assess differences in baseline characteristics
between the GOLD 2011 and GOLD 2017 ABCD groups.
In these analyses, we used Chi-square test and Fisher’s
exact test for categorical variables and Kruskal–Wallis test
for continuous variables (mean (standard deviation) is
given). Descriptive analyses regarding GOLD 2011 and
GOLD 2017 distributions stratified by gender are provided
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in Figures S1 and S2. We further examined the GOLD
2011 and GOLD 2017 distributions stratified by sampling
source (ie, the general population vs the patient popula-
tion) to examine how the distribution differed. In addition,
we estimated Kaplan–Meier curves for mortality outcomes
regarding GOLD 2011 and GOLD 2017 classifications.
The predictive abilities of GOLD 2011, GOLD 2017
ABCD, and GOLD 2017 2A–4D classifications for all-
cause and respiratory mortality and hospitalization were
compared using logistic regression analyses to enable
multivariate post hoc receiver operating curve (ROC) esti-
mations and intramodel area under the curve (AUC) com-
parisons. Both unadjusted analyses and adjusted analyses
with adjustments for gender, age, smoking (yes/no and
pack-years), body mass index, and comorbidities (dia-
betes, angina/heart attack, high blood pressure) were per-
formed. Tests for interactions between GOLD
classifications and gender and age were performed. The
Stata procedures implemented to obtain ROC curves and
AUC comparisons were lroc and roccomp. This procedure
also provides a chi-squared test for difference in AUCs
between two estimated models using the same set of
observations. AUC varies between 0 and 1. An AUC of
1 indicates a perfect diagnostic tool with 100% sensitivity
and 100% specificity. An AUC of 0.5 implies no discrimi-
native value. To supplement the logistic regression ana-
lyses, we performed Cox proportional hazards regression
with Harrell’s C concordance statistic estimates for all
mortality and hospitalization outcomes, using the estat
concordance postestimation tool in Stata. Harrell’s
C corresponds with the area under the Receiver
Operating Characteristic (ROC) curve and ranges from
0.5 to 1, where 0.5 indicates that the model’s prediction
is purely random and 1 indicates that we have perfect
discrimination; the model will predict mortality with
100% accuracy. These analyses are presented in the online
supplement.
Results
Median follow-up time was 91 months, and mean (stan-
dard deviation) follow-up time due to deaths before the
end of follow-up period was 77 (25) months.
Characteristics of the study population by GOLD 2011
and GOLD 2017 ABCD classifications are presented in
Table 1. Based on GOLD 2017 ABCD groups, the
patients with more dyspnea (groups B and D) were
older, reported less current smoking, and coronary heart
disease. They also had more chronic cough, phlegm, and
wheeze, than those with less dyspnea (groups A and C).
These analyses were repeated with gender stratification
(Table S1 and S2), and these analyses showed similar
findings as for the total cohort.
Figure 1 shows the distribution of patients according to
the GOLD 2011 and GOLD 2017 ABCD classifications.
Based on the 2017 categories, fewer patients were classified
in groups C and D, whereas more patients were classified in
group B, as compared to the 2011 classification. Only 2.7%
were in GOLD 2017 group C, encompassing patients with
little dyspnea but numerous exacerbations. As expected,
participants classified as GOLD 2017 group A had more
often lower degree of airflow limitation, whereas group
D had more often a higher degree of airflow limitations
(Table 2). There were no significant gender differences
(Figure 1). Table 3 shows that for GOLD 2011 groups
A and B, most participants received the same ABCD clas-
sification in GOLD 2017. For GOLD 2011 group C, most
participants were classified as group A in GOLD 2017, and
for GOLD 2011 group D, most participants were classified
as group B in GOLD 2017.
The present cohort included patients both from the gen-
eral population and from a hospital registry. As can be seen
from Figure 1C, the majority of subjects recruited from the
general population sample were assigned to groups A and
B, whereas those recruited from the hospital registry were
less often group A, but more often groups B and D.
Mortality
The Kaplan–Meier plots showed that for the GOLD 2017
classification, the overall and respiratory mortality was
increased in GOLD groups B and D as compared to
group A (Figure 2 for respiratory mortality and Figure 2
for all-cause mortality). For the GOLD 2011 classification,
we only observed increased risk for group D. For GOLD
2017 groups 2A–4D, the highest respiratory mortality was
seen in groups 4B and 4D (Figure 3).
Logistic regression analyses of risk of all-cause mortality
and respiratory mortality were performed separately for the
GOLD 2011, GOLD 2017 ABCD, and GOLD 2017 2A–4D
groups (Table 4). For all-cause mortality, group D in GOLD
2011 andGOLD2017ABCDhad the highest risk and groups
4B and 4D had the highest risks in GOLD 2017 2A–4D.
GOLD 2017 group C seemed to have lower all-cause mor-
tality than groups A and B, but results for this group should
be interpreted with caution due to the low number of sub-
jects. For respiratory mortality, increased risk was seen for
GOLD 2011 group D, GOLD 2017 groups B and D, and
Dovepress Le et al
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GOLD 2017 2A–4D groups 2D, 3B, 3D, 4B, and 4D. No
interactions between gender and GOLD 2017 classification
were shown, but there was borderline significant protective
interaction between age and the GOLD 2017 classification
(p-value 0.056 for all-cause mortality and 0.041 for respira-
tory mortality). Receiver operating curve (ROC) statistics for
all-cause mortality of the GOLD 2011, GOLD 2017 ABCD,
and GOLD 2017 2A–4D groups revealed largest AUC for
GOLD 2017 2A–4D groups for all-cause mortality (Table 4
and Figure 4). For respiratory mortality, AUC was higher for
GOLD 2011 as compared to GOLD 2017 ABCD, but highest
AUC was seen for GOLD 2017 2A–4D groups.
The results were further confirmed by the Cox regression
analyses presented in Table S3. Estimations of Harrell’s
C statistics in univariate and multivariate analyses showed
that GOLD 2017 2A–4D classification overall had the best
predictive ability and GOLD 2017 ABCD had lower
predictive ability than GOLD 2011. Predictive ability was
best for respiratory mortality with unadjusted Harrell’s C of
0.73 for GOLD 2011, 0.67 for GOLD 2017 ABCD, and 0.77
for GOLD 2017 2A–4D.
Hospitalization
Logistic regression analyses of risk of all-cause hospitaliza-
tion and respiratory hospitalization were performed sepa-
rately for the GOLD 2011, GOLD 2017 ABCD, and
GOLD 2017 2A–4D groups (Table 5). In these analyses,
GOLD 2011 groups B, C, and D had increased risk of both
all-cause and respiratory hospitalization, GOLD 2017 groups
B and D had increased risk of both all-cause and respiratory
hospitalization and GOLD 2017 groups 2B, 2C, 2D, 3B, 3D,
4B, and 4D had increased risk of both all-cause and respira-
tory hospitalization. The highest risk estimates for respiratory
hospitalization were seen for GOLD 2017 groups 3D, 4B,
Table 1 Characteristics of participants in the GenKOLS study 2003–2005 by GOLD 2011 and GOLD 2017 ABCD classifications
GOLD A GOLD B GOLD C GOLD D p-value
GOLD 2011 classification
N total 193 267 57 395
mMRC dyspnea score 1 (0) 2.6 (0.8) 1 (0) 3.3 (1.1) <0.01
N exacerbations last year 0.1 (0.3) 0.2 (0.4) 0.9 (1.2) 1.1 (1.6) <0.01
% FEV1a 66 (8) 63 (8) 42 (15) 37 (13) <0.01
Male gender, % 66 60 56 60 0.36
Age, yrs 61 (9) 66 (10) 63 (10) 67 (10) <0.01
Current smoker, % 60 47 61 40 <0.01
Pack-years 31 (16) 31 (18) 29 (15) 32 (19) 0.72
BMI, kg/m2 25.5 (4) 26.6 (5) 23.8 (5) 24.7 (5) <0.01
Heart attack/angina, % 9 22 19 21 <0.01
Chronic cough, % 53 74 57 76 <0.01
Phlegm, % 49 64 56 73 <0.01
Wheeze, % 59 77 68 85 <0.01
GOLD 2017 classification
N total 225 476 25 186
mMRC dyspnea score 1 (0) 2.9 (1,0) 1 (0) 3.3 (1.1) <0.01
N exacerbations last year 0.1 (0.3) 0.2 (0.4) 1.8 (1.2) 2.1 (1.7) <0.01
% FEV1a 62 (14) 50 (17) 53 (17) 42 (17) <0.01
Male gender, % 66 61 48 57 0.16
Age, yr 62 (9) 66 (10) 62 (11) 67 (10) <0.01
Current smoker, % 59 46 72 35 <0.01
Pack-years 31 (16) 32 (17) 27 (11) 32 (21) 0.71
BMI, kg/m2 25.2 (4) 25.6 (5) 24.3 (6) 25.3 (5) 0.17
Heart attack/angina, % 12 19 12 30 <0.01
Chronic cough, % 54 75 50 78 <0.01
Phlegm, % 49 66 60 78 <0.01
Wheeze, % 61 80 64 84 <0.01
Notes: aPost-bronchodilator FEV1 in % of predicted.
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Figure 1 Distribution of subjects in GOLD groups. (A) GOLD 2011 classification. (B) GOLD 2017 classification. (C) GOLD 2017 classification, separated by sampling
source (250 subjects from general population and 662 from a patient population).
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and 4D. No interactions between gender and GOLD 2017
classification was shown, but there was borderline significant
interaction between age and the GOLD 2017 classification
for all-cause hospitalizations (p-value 0.046 for all-cause
hospitalization and 0.5 for respiratory hospitalizations).
ROC statistics for all-cause hospitalization showed that
GOLD 2017 2A–4D classification had significantly higher
AUC than GOLD 2011. For respiratory hospitalization,
GOLD 2011 had significantly higher AUC than GOLD
2017 ABCD, but the highest AUC was seen using
GOLD 2017 2A–4D groups.
TheCox regression statistics confirmed the results from the
logistic regression statistics (Table S4). Harrell’s C-statistic
with regard to all-cause hospitalization was, however, the
same for all three classifications with unadjusted values
0.60–0.62. For respiratory hospitalization, the unadjusted
values for GOLD 2011, GOLD 2017 ABCD, and GOLD
2017 2A–4D were 0.72, 0.69, and 0.77, respectively.
Discussion
In the present study of a community-based sample of
COPD patients, we made two main findings. First, the
GOLD 2017 ABCD classification doubles the prevalence
of group B and halves the prevalence of groups C and D as
compared to the GOLD 2011 classification. The ECLIPSE
study showed similar findings.12 Second, the predictive
ability for respiratory mortality and respiratory hospitali-
zation was significantly better when using the GOLD 2011
classification as compared to the GOLD 2017 ABCD
classification. Cabrerea-Lopez et al showed in the BODE
cohort that GOLD 2017 was a less accurate predictor of
mortality than GOLD 2011.13 In the Danish study by
Gedebjerg et al, GOLD 2017 does not predict all-cause
or respiratory mortality more accurately than GOLD
2011.6 The novelty of the present study is, after inclusion
of GOLD airflow limitation severity in GOLD 2017 2A–
4D, GOLD 2017 2A–4D classification has the best
Table 2 GOLD 2011 and GOLD 2017 ABCD classifications by GOLD airflow limitation severity stages 2–4
GOLD airflow limitation severity
Stage 2 Stage 3 Stage 4 Total
GOLD 2011
Group A, N (%) 193 (37.8) 0 0 193 (21.2)
Group B, N (%) 267 (52.4) 0 0 267 (29.3)
Group C, N (%) 10 (2.0) 33 (12.1) 14 (10.8) 57 (6.3)
Group D, N (%) 40 (7.8) 239 (87.9) 116 (89.2) 395 (43.3)
Total, N (%) 510 (55.9) 272 (29.8) 130 (14.3) 912 (100)
GOLD 2017
Group A, N (%) 188 (36.9) 26 (9.6) 11 (8.5) 225 (24.7)
Group B, N (%) 244 (47.8) 163 (59.9) 69 (53.1) 476 (52.2)
Group C, N (%) 15 (2.9) 7 (2.6) 3 (2.3) 25 (2.7)
Group D, N (%) 63 (12.4) 76 (27.9) 47 (36.2) 186 (20.4)
Total, N (%) 510 (55.9 272 (29.8) 130 (14.3) 912 (100)
Table 3 GOLD 2017 ABCD classification by GOLD 2011
GOLD 2011
Group A Group B Group C Group D Total
GOLD 2017
Group A, N (%) 188 (97.4) 0 37 (64.9) 0 225 (24.7)
Group B, N (%) 0 244 (91.4) 0 232 (58.7) 476 (52.2)
Group C, N (%) 5 (2.6) 0 20 (35.1) 0 25 (2.7)
Group D, N (%) 0 23 (8.6) 0 163 (41.3) 186 (20.4)
Total, N (%) 193 (21.2) 267 (29.3) 57 (6.3) 395 (43.3) 912 (100)
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predictive ability for respiratory mortality and respiratory
hospitalizations.
The present study is based on a community-based
sample of COPD patients which consisted of patients
from both the general population and a hospital-based
population. Participants from the general population were
more often classified as groups A or B using both the
GOLD 2011 and 2017 classifications. In the patient popu-
lation of our study, a large number of the patients were
shifted from groups C and D in GOLD 2011 to groups
A and B in GOLD 2017. The shift was explained by the
fact that airway limitation was included in the GOLD
2011, but not in the GOLD 2017 ABCD classification.
This was in accordance with findings by Soriano et al
who showed that the majority of patients in groups C
and D using the GOLD 2011 classification were comprised
by subjects that met the FEV1 criterion alone.4
As expected, we observed higher respiratory mortality and
risk of respiratory hospitalization in groups B and D as com-
pared to group A in all GOLD classifications. This was similar
in the PLATINO study which showed lower mortality rates in
groupsA andB than in groupsC andD for all-causemortality.5
Figure 2 Kaplan–Meier graphs for respiratory mortality for GOLD 2011 and GOLD 2017 ABCD.
Dovepress Le et al
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Figure 3 Kaplan–Meier graph for respiratory mortality for GOLD 2017 2A–4D.
Note: Group 2C, 3C, and 4C are excluded because of the very low number of outcome.
Table 4 Mortality outcomes by GOLD 2011, GOLD 2017 ABCD and GOLD 2017 2A–4D classifications. Univariate and multivariate
logistic regression analyses with post hoc receiver operating curve estimations (8-year follow-up of the GenKOLS study)
All-cause mortality Respiratory mortality










2011 Group A 193 27 1 (ref) 1 (ref) 4 1 (ref) 1 (ref)
2011 Group B 267 64 1.9 (1.2–3.2) 1.3 (0.7–2.3) 13 2.4 (0.8–7.5) 1.9 (0.6–6.0)
2011 Group C 57 9 1.2 (0.5–2.6) 0.8 (0.3–2.1) 2 1.7 (0.3–9.6) 1.2 (0.2–6.8)
2011 Group D 395 187 5.5 (3.5–8.7) 4.0 (2.4–6.7) 90 13.9 (5.0–38.6) 9.6 (3.4–27.1)
AUC (95% CI) 0.68 (0.64–0.71) 0.81 (0.77–0.84) 0.73 (0.69–0.76) 0.82 (0.78–0.86)
2017 Group A 225 34 1 (ref) 1 (ref) 6 1 (ref) 1 (ref)
2017 Group B 476 159 2.8 (1.9–4.3) 2.1 (1.3–3.4) 62 5.5 (2.3–12.8) 4.3 (1.8–10.3)
2017 Group C 25 2 0.5 (0.1–2.2) 0.4 (0.1–2.0) 0 * *
2017 Group D 186 92 5.5 (3.4–8.7) 4.6 (2.7–7.8) 41 10.3 (4.3–24.9) 7.9 (3.2–19.7)
AUC (95% CI) 0.65 (0.62–0.68)a 0.80 (0.77–0.83) 0.66 (0.62–0.70)b 0.79 (0.74–0.83)a
2017 Group 2A 188 26 1 (ref) 1 (ref) 4 1 (ref) 1 (ref)
2017 Group 2B 244 53 1.7 (1.0–2.9) 1.2 (0.7–2.1) 10 2.0 (0.6–6.4) 1.5 (0.4–4.9)
2017 Group 2C 15 1 * * 0 * *
2017 Group 2D 63 25 4.1 (2.1–7.9) 2.6 (1.2–5.6) 9 7.7 (2.3–25.9) 4.7 (1.3–17.1)
2017 Group 3A 26 5 1.5 (0.5–4.3) 0.8 (0.3–2.6) 0 * *
2017 Group 3B 163 64 4.0 (2.4–6.8) 2.5 (1.4–4.4) 26 8.7 (3.0–25.6) 5.4 (1.8–16.3)
2017 Group 3C 7 0 * * 0 * *
2017 Group 3D 76 35 5.3 (2.9–9.8) 3.8 (1.9–7.6) 14 10.4 (3.3–32.7) 7.3 (2.2–24.2)
2017 Group 4A 11 3 2.3 (0.6–9.4) 2.1 (0.5–9.7) 2 * *
2017 Group 4B 69 42 9.7 (5.1–18.3) 8.1 (4.0–16.6) 26 27.8 (9.2–83.9) 19.8 (6.3–61.8)
2017 Group 4C 3 1 * * 0 * *
2017 Group 4D 47 32 13.3 (6.3–27.9) 14.0 (6.0–32.6) 18 28.6 (9.0–90.4) 21.5 (6.4–71.9)
AUC (95% CI) 0.71 (0.67–0.74)b,c 0.83 (0.79–0.85)a,c 0.77 (0.73–0.82)b,c 0.84 (0.80–0.87)a,c
Notes: *Odds ratio not reported for groups with three or fewer outcomes due to uncertain estimates. **Adjusted for gender, age, smoking, body mass index, comorbidities
(diabetes, angina/heart attack, high blood pressure). ap<0.05 and bp<0.001 as compared with GOLD 2011 ABCD. cp<0.001 as compared with GOLD 2017 ABCD.
Abbreviations: AUC, area under the curve; CI, confidence interval; OR, odds ratio.
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Johannessen et al found that the predictive ability of GOLD
2011 in terms of respiratory mortality and respiratory hospita-
lization did not differ significantly from the predictive ability of
the airflow limitation severity stages used in the GOLD 2007
classification.3 In the present study, the predictive ability for
respiratorymortality ofGOLD2011 is however better than that
of the GOLD 2017 ABCD classification. The GOLD 2A–4D
classification with inclusion both of grade 1–4 of airflow
limitation severity and symptom and exacerbation history
(groups ABCD) did however show the best predictive ability.
It has been argued that airflow limitation severity loses preci-
sion at the individual patient level and thus cannot be used
alone to determine therapeutic options.2 In the GOLD 2017
classification, airflow limitation was therefore separated from
symptoms and exacerbations, and the pharmacological treat-
ment was targeted according to the assessment of symptoms or
risk of exacerbations. Celli et al, however, reported airflow
limitation (FEV1) to be the best single correlate of mortality.14
In the ECLIPSE study, the best single predictor of all-cause
mortality was FEV1.12 Severity of airflow limitation is a key
risk factor for exacerbation requiring hospitalization.15 In our
study, airflow limitation rate has important prognostic impor-
tance for respiratory mortality and respiratory hospitalization
(exacerbations), andwith registry data suggesting that dynamic
improvement in GOLD severity is associated with improved
outcomes, and vice versa16 this aspect cannot be ignored in
patientmanagement. Hence, although theABCDclassification
in GOLD 2017 is simpler in clinical practice, our and others
Figure 4 Comparison of univariate area-under-the curve analyses for GOLD 2011, GOLD 2017 ABCD, and GOLD 2017 2A–4D. Separate analyses for all-cause mortality
and respiratory mortality.
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findings indicate that airflow limitation is an important para-
meter that should be included in prognostic assessments. Our
observation therefore adds to other observations in the evol-
vingfield of precision-basedmedicine on establishing themost
relevant predictive factors for risk of death and other outcomes
in people with COPD. Since others have identified that com-
bining age with dyspnea and airway obstruction is superior to
other models in predicting death,17 one area for future research
could be to assess whether incorporating age to the GOLD
2017 2A–4D further enhanced the predictability.
In our study, 2% of the participants from the general
population and 3% from the patient population were classi-
fied as group C in GOLD 2017. A similar result was shown in
the population-based PLATINO study of the 2011 GOLD
classification in which 10 of 524 COPD patients (1,9%) were
classified in group C.5 Soriano et al argued that class C in
2011 classification might be superfluous.4 Our data indicate
that this might be the same in the 2017 classification and that
while group C conferred no increased risk for all-cause or
respiratory mortality, risks for all-cause or respiratory hospi-
talization were at the level of group B.
The most prominent strength of the present study is the
large and robust population with complete follow-up data. The
study is based on an extensive amount of information gathered
from each of the 912 participants in the study population. The
length of the follow-up period, which is essential when it
comes to mortality in a middle-aged population, was a solid
eight years. Furthermore, all death certificateswere thoroughly
validated.7 Even though the limited sample size in GOLD
group C might have limited the study in respect to identifying
possible statistically significant associations, the material at
hand should be extensive enough to provide a statistically
Table 5 All-cause and Respiratory hospitalizations (0 OR≥1) by GOLD 2011 and GOLD 2017 classifications and Univariate and
Multivariate logistic regression analyses with post hoc receiver operating curve estimations



















2011 Group A 193 119 1 (ref) 1 (ref) 10 1 (ref) 1 (ref)
2011 Group B 267 223 3.2 (2.0–4.9) 2.3 (1.5–3.7) 45 3.7 (1.8–7.6) 3.5 (1.6–7.5)
2011 Group C 57 47 2.9 (1.4–6.1) 3.0 (1.3–6.6) 11 4.4 (1.8–10.9) 3.9 (1.5–10.3)
2011 Group D 395 351 5.0 (3.2–7.6) 3.7 (2.3–5.8) 179 15.2 (7.8–29.5) 14.8 (7.2–30.1)
AUC (95% CI) 0.66 (0.62–0.71) 0.77 (0.74–0.81) 0.73 (0.70–0.76) 0.78 (0.74–0.81)
2017 Group A 225 143 1 (ref) 1 (ref) 16 1 (ref) 1 (ref)
2017 Group B 476 401 3.1 (2.1–4.4) 2.4 (1.6–3.5) 132 5.0 (2.9–8.7) 4.9 (2.8–8.7)
2017 Group C 25 23 6.6 (1.5–28.7) 8.5 (1.9–38.9) 5 3.3 (1.1–9.8) 2.9 (0.9–9.1)
2017 Group D 186 173 7.6 (4.0–14.3) 5.4 (2.8–10.3) 92 12.8 (7.1–22.9) 12.3 (6.6–22.8)
AUC (95% CI) 0.68 (0.64–0.72) 0.78 (0.75–0.82) 0.69 (0.66–0.72)a 0.75 (0.71–0.78)a
2017 Group 2A 188 114 1 (ref) 1 (ref) 10 1 (ref) 1 (ref)
2017 Group 2B 244 201 3.0 (2.0–4.7) 2.4 (1.5–3.8) 33 2.8 (1.3–5.8) 2.7 (1.2–5.9)
2017 Group 2C 15 13 4.2 (0.9–19.2) 5.3 (1.1–25.3) 3 4.5 (1.1–18.3) 4.4 (1.0–19.1)
2017 Group 2D 63 60 13.0 (3.9–42.9) 6.6 (1.9–22.6) 25 11.7 (5.2–26.4) 9.7 (4.0–23.4)
2017 Group 3A 26 20 2.2 (0.8–5.6) 1.5 (0.5–4.2) 4 3.2 (0.9–11.2) 2.9 (0.8–10.2)
2017 Group 3B 163 138 3.6 (2.1–6.0) 2.5 (1.5–4.4) 56 9.3 (4.6–19.0) 8.8 (4.1–18.8)
2017 Group 3C 7 7 * * 1 * *
2017 Group 3D 76 68 5.5 (2.5–12.1) 3.8 (1.7–8.8) 40 19.8 (9.1–43.1) 19.5 (8.5–44.9)
2017 Group 4A 11 9 2.9 (0.6–13.9) 3.9 (0.8–20.0) 2 * *
2017 Group 4B 69 62 5.8 (2.5–13.2) 4.8 (2.0–11.4) 43 29.4 (13.2–65.6) 32.2 (13.7–75.6)
2017 Group 4C 3 3 * * 1 * *
2017 Group 4D 47 45 14.6 (3.4–62.0) 13.9 (3.2–60.7) 27 24.0 (10.2–56.8) 27.8 (11.1–69.7)
AUC (95% CI) 0.69 (0.65–0.73)a 0.79 (0.75–0.82)a 0.77 (0.74–0.80)b,c 0.80 (0.77–0.84)b,c
Notes: *Odds ratio not reported for groups with three or fewer outcomes due to uncertain estimates. **Adjusted for gender, age, smoking, body mass index, comorbidities
(diabetes, angina/heart attack, high blood pressure). ap<0.05 and bp<0.001 as compared with GOLD 2011 ABCD. cp<0.001 as compared with GOLD 2017 ABCD.
Abbreviations: AUC, area under the curve; CI, confidence interval; OR, odds ratio.
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sound basis for the analysis and the conclusions.
Characteristics of our included patients are also similar to
other studies, eg, the PLATINO study and the study by Flynn
et al and our results should thus be valid also for other
populations.5,16 For the scope of our study, numerous statistical
methodologies could have been implemented. One option at
hand is the Cohen’s Kappa in descriptive analyses to add to the
understanding of accordance between the GOLD 2011 and
GOLD 2017 classifications. Avaluable alternative to the inter-
model discrimination investigation we have performed could
also have been to assess if each model was well calibrated or
not (ie, how similar the expected and observed event rates are
in subgroups of the population) using the Hosmer–Lemeshow
test. Also other statistics could be used to compare the prog-
nostic ability of the classifications, for example, calculations of
NRI and/or IDI.18 The methodologies used in the present
study – logistic regression to enable multivariate posthoc
ROC curve estimations and intramodel AUC comparisons,
and Cox regression with posthoc Harrell’s C concordance
statistic estimations – are tailored to match the study by
Johannessen et al comparing the GOLD 2007 and GOLD
2011 classifications.3 The present study is a continuation of
the study by Johannessen et al, based on the same study
population and moving the focus from GOLD 2007 vs
GOLD 2011 to GOLD 2011 vs GOLD 2017.
A weakness is that the cohort does not include GOLD
stage 1 participants. However, since 96–99% of GOLD stage
I participants probably would be assigned to the low-risk
groups A or B,19,20 the included GOLD stages 2–4 are
clinically most significant. The primary aim of the GOLD
classifications is not to provide long-term prognosis, but
rather to provide a consistent framework for the more
immediate treatment and follow-up. Thus, it could be argued
that the present study’s long-term focus is of less importance.
We counter that by pointing out that a more complete picture
of the predictive ability of the GOLD 2017 classification
potentially might improve long-term planning. Through bet-
ter planning of long-term treatment, better management of
early interventions and systematic follow-up of high-risk
patients, all based on baseline characteristics, prognosis
might be improved. GenKOLS was not designed to test the
predictive ability of the GOLD classifications, and only the
severe COPD exacerbations leading to hospitalization are
recorded as outcome. Unfortunately, that leaves out valuable
information about mild or moderate exacerbations from the
available material. The result of this study may not be
extended to all COPD patients because three out of four
participants are general population, were identified from
a hospital registry. Lastly, the CAT score is not recorded,
while the alternative21 mMRC score was recorded and used,
application of both the CAT and mMRC scores would have
increased the proportion of patients classified as groups
B and D. Further, we do not adjust for dynamic changes in
GOLD stages, which might have lead to under- or over-
estimation of association with outcomes. The result of this
study may not be extended to all COPD patients because
three out of four participants are general population, were
identified from a hospital registry.
In conclusion, GOLD 2011 had better predictive ability
than GOLD 2017 ABCD, but after inclusion of airflow
limitation severity in GOLD 2017 2A–4D, GOLD 2017
2A–4D had best predictive abilities. GOLD 2017 ABCD
might be easier for clinicians in terms of therapeutic options
because it is less complex, but the cost seems to be lower
predictive ability. One might question whether GOLD 2017
group C is justified as few patients seem to be classified into
this group. Our findings need confirmation in further studies,
but our study shows that airflow limitation (grade 1–4)
should be included in the classification of COPD patients.
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Supplementary material
Inclusion and exclusion criteria for
the GenKOLS study
Common inclusion criteria for both cases and controls were:
1. Self-reported Caucasian.
2. Age ≥40 years.
3. Current or ex-smoker with a minimum of 2.5 pack-years.
4. No severe alpha-1 antitrypsin deficiency (ZZ, Z Null,
Null-Null or SZ) assessed by PI type.
5. No previous chronic pulmonary disorder (other than
COPD for the cases). Inactive tuberculosis and pre-
vious diagnosis of asthma were not exclusion criteria.
6. No HIV, hepatitis B or C, dementia, severe anemia
(defined as hemoglobin≤9.0g/dL), previous organ
transplantation, or lung–volume reduction surgery.
7. No antibiotics for respiratory diseasewithin 1month of the
visit, and no respiratory infection within 6 weeks of the
visit.
8. Able and willing to sign an informed consent form.
In addition, cases were required to have spirometry-
defined COPD with a postbronchodilator (post-BD)
FEV1/FVC<0.7 and FEV1<80% (GOLD stage II or
worse). Controls were required to have post-BD
FEV1/FVC≥0.7 and FEV1≥80%. Predicted values
of FEV1 were assessed using equations from
a Norwegian reference population.










mMRC dyspnea score, mean (SD) 1 (0) 3.0 (1.1) 1 (0) 3.3 (1.2) <0.001
Exacerbations last year, mean (SD) 0.1 (0.4) 0.2 (0.4) 2.1 (1.6) 2.5 (2.1) <0.001
% pred.post-bd FEV1, mean (SD) 60 (12) 49 (17) 54 (18) 45 (17) <0.001
Age (yrs), mean (SD) 61 (8.4) 65 (9.9) 66 (9.6) 65 (10.1) 0.02
Current smokers (%) 69 49 54 43 0.01
Pack years, mean (SD) 26 (14) 28 (14) 23 (12) 24 (14) 0.21
BMI (kg/m2), mean (SD) 25 (5) 25 (6) 24 (6) 25 (6) 0.61
Diabetes (%) 3 5 8 4 0.91
Heart attack/angina (%) 3 14 15 23 0.02
High blood pressure (%) 25 26 15 26 0.85
Chronic cough (%) 52 77 67 75 0.08
Phlegm (%) 48 62 38 80 0.001
Wheeze (%) 60 81 54 86 <0.001
All-cause admission days per year 2.1 (3) 4.4 (4) 3.9 (3) 6.3 (6) <0.001
Respiratory admission days per year 0.1 (0) 1.1 (3) 0.5 (1) 2.0 (4) <0.001
All-cause mortality (%) 10 31 0 45 <0.001
Respiratory mortality (%) 4 14 0 25 0.001
Cardiovascular mortality (%) 3 4 0 4 0.81
Note: Overall test for equality of populations: Chi-square test for categorical variables with >5 observations in each cell, Fisher’s exact test for categorical variables with <5
observations in a cell (diabetes, heart attack, all-cause, respiratory, and cardiovascular mortality), and Kruskal–Wallis test for continuous variables. N=355.
Abbreviations: mMRC, modified Medical Research Council dyspnea score; post-bd FEV1, post-bronchodilator forced expiratory volume in 1 s; BMI, body mass index.
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mMRC dyspnea score, mean (SD) 1 (0) 2.8 (1.0) 1 (0) 3.3 (1.0) <0.001
Exacerbations last year, mean (SD) 0.1 (0.3) 0.1 (0.3) 1.6 (0.8) 1.9 (1.3) <0.001
% pred.post-bd FEV1, mean (SD) 62 (14) 50 (17) 51 (18) 40 (16) <0.001
Age (yrs), mean (SD) 62 (9.5) 67 (10.2) 58 (10.9) 68 (9.6) <0.001
Current smokers (%) 54 43 92 29 <0.001
Pack years, mean (SD) 34 (17) 35 (19) 31 (10) 39 (23) 0.47
BMI (kg/m2), mean (SD) 26 (4) 26 (4) 25 (6) 25 (5) 0.22
Diabetes (%) 5 7 0 11 0.30
Heart attack/angina (%) 16 22 8 35 0.003
High blood pressure (%) 32 31 8 30 0.39
Chronic cough (%) 55 73 38 80 0.004
Phlegm (%) 50 69 83 76 <0.001
Wheeze (%) 61 80 75 82 0.001
All-cause hosptalizations per year 2.1 (3) 4.2 (4) 3.8 (6) 7.1 (6) <0.001
Respiratory hospitalizations days per year 0.1 (1) 0.7 (2) 1.3 (5) 1,9 (4) <0.001
All-cause mortality (%) 18 35 17 53 <0.001
Respiratory mortality (%) 2 13 0 20 <0.001
Cardiovascular mortality (%) 1 5 8 6 0.21
Notes: N=557. *Overall test for equality of populations: Chi-square test for categorical variables with >5 observations in each cell, Fisher’s exact test for categorical
variables with <5 observations in a cell (diabetes, heart attack, all-cause, respiratory and cardiovascular mortality), and Kruskal–Wallis test for continuous variables.
Abbreviations: mMRC, modified Medical Research Council dyspnea score; post-bd FEV1, post-bronchodilator forced expiratory volume in 1 s; BMI, body mass index.
Table S3 Mortality outcomes by GOLD 2011 and GOLD 2017 classifications, unadjusted and adjusted cox regression statistics
All-cause mortality Respiratory mortality








2011 group A 1 1 1 1
2011 group B 1.8 (1.2–2.9) 1.4 (0.9–2.3) 2.5 (0.8–7.7) 2.0 (0.6–6.3)
2011 group C 1.2 (0.5–2.5) 0.9 (0.4–2.0) 1.7 (0.3–9.4) 1.1 (0.2–6.3)
2011 group D 4.3 (2.8–6.4) 2.9 (1.9–4.5) 13.7 (5.0–37.4) 9.2 (3.3–25.3)
Harrell’s C*** 0.65 0.75 0.73 0.82
2017 group A 1 1 1 1
2017 group B 2.5 (1.7–3.6) 1.9 (1.2–2.8) 5.4 (2.3–12.6) 4.3 (1.8–10.1)
2017 group C 0.5 (0.1–2.1) 0.4 (0.1–1.8) Omitted Omitted
2017 group D 4.1 (2.7–6.0) 2.9 (1.9–4.4) 10.1 (4.3–23.9) 6.9 (2.9–16.6)
Harrell’s C*** 0.62 0.75 0.67 0.80
2017 group 2A 1 1 1 1
2017 group 2B 1.7 (1.0–2.6) 1.2 (0.7–2.0) 2.0 (0.6–6.5) 1.5 (0.4–5.1)
2017 group 2D 3.3 (1.9–5.7) 2.1 (1.2–3.8) 7.7 (2.3–25.1) 4.8 (1.4–16.1)
2017 group 3B 3.3 (2.1–5.2) 2.2 (1.4–3.5) 8.6 (3.0–24.8) 5.5 (1.9–16.2)
2017 group 3D 4.0 (2.4–6.7) 2.8 (1.6–4.8) 10.6 (3.5–32.3) 7.1 (2.3–22.2)











Notes: Multivariate models adjusted for gender, age, smoking, body mass index, comorbidities (diabetes, angina/heart attack, high blood pressure). ***Posthoc estimation of
Harrel's C concordance statistic following Cox regression.
Le et al Dovepress
submit your manuscript | www.dovepress.com
DovePress



















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Table S4 All-cause and respiratory hospitalization by GOLD 2011 and GOLD 2017 classifications, univariate and multivariate* Cox
proportional hazards regression analyses
All-cause hospitalizations Respiratory hospitalizations








2011 group A 1 1 1 1
2011 group B 1.8 (1.3–2.3) 1.6 (1.2–2.1) 1.9 (0.8–4.5) 2.0 (0.8–5.2)
2011 group C 1.7 (1.1–2.6) 1.6 (1.0–2.4) 2.7 (0.9–8.5) 2.6 (0.8–8.4)
2011 group D 2.4 (1.8–3.1) 2.0 (1.5–2.6) 9.1 (4.2–19.6) 9.6 (4.1–22.1)
Harrell’s C** 0.60 0.66 0.72 0.77
2017 group A 1 1 1 1
2017 group B 1.9 (1.5–2.4) 1.6 (1.3–2.1) 5.8 (2.9–11.6) 5.6 (2.7–11.6)
2017 group C 2.7 (1.5–4.7) 3.5 (2.0–6.3) 5.7 (1.5–21.0) 8.1 (2.1–30.8)
2017 group D 3.0 (2.2–4.0) 2.6 (1.9–3.5) 12.1 (5.7–25.4) 11.9 (5.4–26.2)
Harrell’s C** 0.61 0.67 0.69 0.78
2017 group 2A 1 1 1 1
2017 group 2B 1.7 (1.3–2.3) 1.5 (1.2–2.0) 2.1 (0.8–5.3) 2.2 (0.8–5.8)
2017 group 2D 3.2 (2.0–4.9) 2.3 (1.5–3.7) 9.4 (3.3–26.7) 7.7 (2.6–23.3)
2017 group 3B 2.0 (1.5–2.8) 1.7 (1.2–2.3) 9.9 (4.4–22.3) 8.3 (3.4–20.0)
2017 group 3D 2.4 (1.6–3.6) 2.1 (1.3–3.2) 12.4 (5.0–30.7) 13.2 (5.0–34.8)
2017 group 4B 2.7 (1.8–4.0) 2.2 (1.5–3.3 19.7 (8.5–45.7) 20.3 (8.1–50.7)
2017 group 4D 5.1 (3.1–8.3) 5.5 (3.3–9.1 26.6 (10.1–70.3) 36.5 (12.7–104.5)
Harrell’s C** 0.62 0.68 0.77 0.83
Notes: *Multivariate models adjusted for gender, age, smoking, body mass index, comorbidities (diabetes, angina/heart attack, high blood pressure). **Posthoc estimation of
Harrel's C concordance statistic following Cox regression.
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Figure S1 Distribution (%) of female and male by GOLD 2011 classification and by GOLD 2017 classification.
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Figure S2 Kaplan–Meier graphs for all-cause mortality according to GOLD 2011, GOLD 2017 ABCD and GOLD 2017 2A–4D.
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